Chesahna Kindred, M.D., MBA, FAAD, and Renata Block, PA-C, describe how ruxolitinib works differently from other topicals traditionally used in the treatment of vitiligo.
Experts review the benefits and side effects of off-label treatments for patients with vitiligo such as corticosteroids, tacrolimus, pimecrolimus or calcipotriene (in combination with corticosteroids).
How an open marketplace impacts future competition, pricing transparency, and formulary management.
As more therapeutic options become available, individualizing treatment for hemophilia A becomes increasingly important.
The potential benefits and uncertainties surrounding gene therapy include its curative potential, the need for immunosuppression, ongoing care needs, and a lack of long-term data.
The evolving hemophilia treatment landscape necessitates informed discussions around patient-centered therapy choices that consider patient lifestyle, treatment goals, and thrombotic risks.
Discussion on cost inputs involved in the cost-efficiency analysis which includes: medication cost, REBYOTA cost, imaging cost, out-patient visit costs, and more.
Goldsack also pointed to Podimetrics and its SmartMat product, which detects the warning signs of diabetic foot ulcers, as a digital health success story: “That is the sort of thing we want to see.”
Experts explain their approach to the treatment of a new patient with vitiligo and the role of phototherapy in their practice.